停用双膦酸盐后非典型股骨应力骨折仍进展
报告一例70岁骨量减少女性,阿仑膦酸钠治疗9年后出现右大腿痛及双股骨外侧皮质异常,停药4年后右股骨出现不完全非典型股骨骨折并预防性髓内钉固定,7年后左股骨出现早期不完全骨折。特立帕肽治疗1.5年后左股骨透亮线消失但右股骨未消失,提示停药后骨折仍可进展,需随访并可能受益于合成代谢治疗。
要点
- 长期双膦酸盐使用后,即使停药,不完全非典型股骨骨折仍可能进展。
- 对股骨中段应力骨折患者应进行随访,监测对侧及同侧病变进展。
- 特立帕肽可能促进早期不完全非典型股骨骨折愈合,但需个体化评估。
核心结论
- 长期双膦酸盐暴露患者的不完全非典型股骨骨折在停药后仍可进展,需长期随访。
研究设计与样本
- 本文为个案报告,描述一例70岁骨量减少女性长期阿仑膦酸钠治疗后的非典型股骨骨折进展过程。
主要发现
- 患者阿仑膦酸钠治疗9年,停药4年后右股骨出现不完全非典型股骨骨折并接受预防性髓内钉固定。
- 停药7年后左股骨出现三个小水平线状透亮缺陷,符合早期不完全非典型骨折。
- 特立帕肽治疗1.5年后左股骨透亮缺陷消失,但右股骨未消失,双股骨外侧皮质异常增厚持续存在。
临床怎么用
- 对长期双膦酸盐使用后出现股骨中段应力骨折的患者,即使停药也应定期影像学随访。
- 不完全非典型股骨骨折患者可考虑特立帕肽等合成代谢治疗以促进愈合。
- 需平衡不完全非典型股骨骨折进展风险与骨质疏松性骨折风险,个体化决策。
局限性
- 个案报告,结论不能推广至所有长期双膦酸盐使用患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atypical femur fracture (AFF) is an uncommon complication of long-term bisphosphonate use, but the risk declines substantially after treatment cessation. We report a case of a 70-year-old woman with osteopenia treated with alendronate for 9 years who presented with right mid-thigh pain and radiographic findings of focal lateral cortical thickening in the right mid-femur and lateral cortex irregularity in the proximal-mid left femur. Alendronate was discontinued, but she remained on estrogen for menopausal symptoms. Four years later, a horizontal linear translucent defect was seen in the right mid-femur area of cortical hypertrophy, consistent with an incomplete AFF. The patient underwent prophylactic intramedullary rodding of the right femur and estrogen was discontinued. Three years later (7 years after initial presentation), the cortical irregularities in the left femur were more prominent and three small horizontal linear translucent defects were now evident, consistent with early incomplete atypical fracture development. The patient also suffered a wrist fracture. She was treated with teriparatide for 1.5 years with resolution of the translucent defects in the left but not the right femur, although abnormal thickening of the lateral cortex persisted in both femurs. Our case demonstrates incomplete atypical femur fracture progression in a patient with long-term bisphosphonate exposure, even after treatment cessation. These findings highlight the importance of follow-up for patients who develop diaphyseal femur stress fractures and the potential for early healing with anabolic therapy. This case also demonstrates the challenge in managing older patients with incomplete AFF at risk for progression to complete AFF and osteoporotic fracture.
引用
- Gu KD, Ettinger B, Grimsrud CD, et al. Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy. Osteoporos Int. 2021. PMID: 33914104. doi:10.1007/s00198-021-05948-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。